Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(50.0%)
Phase 3
1(12.5%)
Phase 1
1(12.5%)
Phase 2
1(12.5%)
Phase 4
1(12.5%)
8Total
N/A(4)
Phase 3(1)
Phase 1(1)
Phase 2(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT02867033Not ApplicableActive Not Recruiting

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

Role: collaborator

NCT02505750Phase 3Active Not Recruiting

Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

Role: collaborator

NCT02907554Phase 4Completed

Cyclosporine a Pretreatment and Kidney Graft Function

Role: collaborator

NCT05897879Not ApplicableRecruiting

Impact of Bacterial Expression and Immune Response in the Severity of Pertussis

Role: collaborator

NCT05953558Recruiting

French Cohort Evaluating the effectiveneSs of Atrioventricular Synchrony by the micRa AV

Role: collaborator

NCT05131633Completed

Regional Anaesthesia in Intensive Care Unit

Role: collaborator

NCT05302115Unknown

S-ICD French Cohort Study (HONEST)

Role: collaborator

NCT01861860Not ApplicableCompleted

OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA

Role: collaborator

NCT01857453Phase 2Unknown

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Role: collaborator

NCT01808885Phase 1Completed

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

Role: collaborator

NCT01541527Withdrawn

Non Neutralizing Antibodies: Prevalence and Characterization

Role: collaborator

NCT02099422Unknown

Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome

Role: lead

NCT01689493Not ApplicableCompleted

Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation

Role: lead

All 13 trials loaded